NanoVibronix has completed its acquisition of ENvue Medical Holdings, a privately-held provider of enteral feeding solutions.

NanoVibronix believes the transaction will bolster the combined company’s market position in enteral feeding tech and therapeutic medical devices. ENvue’s proprietary tech aligns with its commitment to patient safety and advanced medical solutions.

The acquisition of ENvue was structured as a stock-for-stock transaction. All of ENvue’s outstanding equity interests were exchanged based on a fixed exchange ratio for consideration as a combination of 1,734,995 shares of the company common stock.

A successor-in-interest of ENvue will become a wholly-owned subsidiary of NanoVibronix.

Concurrently, the company consummated a private placement investment with an institutional investor, pursuant to which it sold in a private placement a senior convertible debenture with aggregate principal amount of $500,000.

NanoVibronix and ENvue will continue to be led by its current management team, with the addition of Doron Besser of ENvue and Professor Zeev Rotstein as directors, and resignation of Harold Jacob, M.D., Maria Schroeder and Michael Ferguson from the board of directors of the company.

“This transaction represents a transformational opportunity for NanoVibronix and our shareholders,” said NanoVibronix CEO Brian Murphy. “ENvue Medical has developed an innovative solution that directly addresses critical patient safety challenges in enteral feeding, and we are excited to integrate their technology into our portfolio. Together, we are positioned to accelerate growth, improve patient outcomes and create long-term value for our shareholders.”

“Joining forces with NanoVibronix marks the beginning of an exciting new chapter for ENvue Medical,” added ENvue CEO Dr. Doron Besser. “Our combined expertise, market presence and commitment to innovation will allow us to reach more hospitals and healthcare providers with life-saving solutions. We look forward to bringing our cutting-edge enteral feeding technology to a broader audience and making a meaningful impact in patient care.”

Earlier this week, the company announced it had completed the first phase of a randomized controlled trial of its UroShield surface acoustic wave portable ultrasound therapeutic device by University of Michigan (UM) researchers.